Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc., a Delaware corporation and emerging growth company, on August 11, 2025. The report covers events occurring between August 11, 2025, and August 15, 2025, regarding changes in senior financial leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Departure of Principal Financial Officer: Andrew Walsh resigned as Vice President of Finance and Principal Financial Officer, effective August 22, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment of Acting CFO: On August 15, 2025, the Board of Directors unanimously appointed Maria Maccecchini, the Company's Chief Executive Officer, to serve as Acting Chief Financial Officer.
- Recruitment Status: The Company is actively searching for a permanent replacement for the Chief Financial Officer role.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational transition of the finance department. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of Andrew Walsh's departure (August 22, 2025) and the interim leadership structure.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Verify that the transition of financial duties to the CEO does not impact the timing of upcoming financial reporting or audit processes.